AsianFin -- Novo Nordisk announced on Wednesday a comprehensive company-wide transformation aimed at streamlining its organizational structure, accelerating decision-making, and reallocating resources toward growth opportunities in diabetes and obesity.

As part of the restructuring, the Danish pharmaceutical giant plans to cut approximately 9,000 positions worldwide—about 5,000 of which are expected in Denmark—out of its current workforce of 78,400. The company anticipates that the cost-saving measures will yield annualized savings of 8 billion Danish kroner by the end of 2026.